Justin F. Gainor, MD

Justin F. Gainor, MD, director of the Center for Thoracic Cancers and Targeted Immunotherapy at Massachusetts General Hospital, discusses the latest advancements with immune checkpoint inhibitors for the treatment of patients with nonsmall cell lung cancer (NSCLC).

Checkpoint inhibitors have transformed the management of advanced NSCLC, where the agents have been moved to earlier lines in the disease course, Gainor says. The first evidence to demonstrate benefit in this setting, which ultimately launched further evaluation, was the

. Patients with locally advanced NSCLC who completed the standard of care chemotherapy and radiation went on to receive a checkpoint inhibitor, durvalumab (Imfinzi), as consolidation therapy. This led to an improvement in both the progression-free survival and overall survival rates.

Videos

Justin F. Gainor, MD, discusses the latest advancements with immune checkpoint inhibitors for the treatment of patients with non&mdash;small cell lung cancer.

Checkpoint Inhibitors Advance Standard of Care for Non-Small Cell Lung Cancer

Justin F. Gainor, MD, medical oncologist, Assistant Professor of Medicine, Massachusetts General Hospital, Harvard Medical School, discusses how the treatment paradigm for EGFR+ lung cancer will transform over the next several years.

Justin F. Gainor, MD | Authors

Articles

Checkpoint Inhibitors Advance Standard of Care for Non-Small Cell Lung Cancer

How the Treatment Paradigm for EGFR+ Lung Cancer Will Transform